Study claims 2026 horror film set new audience heart‑rate recordSpanish Prime Minister Sánchez replies to Jeff Bezos' remarks on housing costsCars torched and shops looted during anti‑migrant protests in South AfricaUkraine reports battlefield gains with drone support amid ongoing Russian airstrikesLeBron James debuts with 76ers in preseason as Nets secure victoryAfghan couple reflects on 25-year aftermath of U.S. invasionBosnia and Herzegovina to elect new Grand Mufti on October 10Former NZ PM Helen Clark says EU associate membership would be "very interesting" for New ZealandFinland faces growing debt concerns amid Ukraine war impactsTwo German officials killed during routine firearms inspection in Bavaria; suspect arrested after standoffBritain's nuclear submarines reportedly use fire hoses to counter drone attacksTwo Spanish cities awarded European Green Capital 2028Polish committee to recommend parliamentary vote on trial of central bank governorIndiana State Police arrest Hancock County deputy on multiple misconduct and fraud chargesFormer President Obama endorses Pennsylvania Governor Josh Shapiro's reelection bid
Politifex
Search
Back to event
Federal RegisterGovernmentRegulationControlled Substances ActDrug Enforcement AdministrationPrescription Drug RegulationNarcotics and Non-narcotic Drugs

Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products

By Justice Department, Drug Enforcement Administration · Oct 8, 2026, 11:00 PM CDT

Read full article at Federal Register
The Drug Enforcement Administration (DEA) is revoking the exempted status for certain nonnarcotic prescription products that are currently on DEA's Table of Exempted Prescription Products, but whose National Drug Codes (NDC) are inactive because they are no longer available and/or the company that applied for the exemption no longer exists. These products will be removed from DEA's Table of Exempt

Excerpt shown under fair-use limits. Full text remains with the original publisher.

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation
INSUFFICIENT CONTEXT
Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

Neutral languageThe statement uses straightforward, descriptive language without emotive or persuasive wording.

Lack of detailThe announcement provides the outcome but omits background on why the change is necessary or its broader implications.

Context

AI analysis

Missing context

The announcement does not explain the criteria used to determine which inactive NDCs are removed, the timeline for implementation, the potential impact on prescribers or patients, or whether any public comment period was offered.

Important context

The Table of Exempted Prescription Products lists non‑controlled substances that are exempt from certain DEA registration requirements. Removing inactive entries clarifies the list and ensures that only currently available products retain exempt status, which may affect regulatory compliance for pharmacies and manufacturers.

Opinion vs. reporting

AI analysis

The text is purely factual and does not contain opinion; it reports an administrative action by the DEA.